A Study of Intravenous Aflibercept With Docetaxel in Chinese Patients With Solid Tumors

The duration of screening, treatment, and follow-up are within 21 days, 3 weeks/cycle, and 90 days after the last aflibercept administration. Patients will be administered aflibercept in combination with docetaxel until when/if a definitive treatment discontinuation criterion is met such as progressive disease, unacceptable toxicity or patient refusal to continue.

Inclusion criteria

• Histologically or cytologically confirmed solid malignancy that metastatic or unresectable for which standard curative measures do not exist, but for which docetaxel treatment is appropriate.

Exclusion criteria

• Squamous histology/cytology lung cancer
• Need for a major surgical procedure or radiation therapy during the study
• Treatment with chemotherapy, hormonal therapy, radiotherapy, surgery, or an investigational agent within 28 days
• Cumulative radiation therapy to >25% of the total bone marrow
• History of brain metastases
• Eastern Cooperative Oncology Group(ECOG)>1
• Prior docetaxel treatment but have not been appropriate for safety reasons
• Inadequate organ and bone marrow function
• Uncontrolled hypertension
• Evidence of clinically significant bleeding diathesis or underlying coagulopathy

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.